Clinical trial
Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma
NCT00210366 · International Extranodal Lymphoma Study Group (IELSG), Other · Terminated
Key facts
| NCT number | NCT00210366 |
|---|---|
| Title | Salvage Therapy With Idarubicin in Relapsing CNS Lymphoma |
| Official title | Salvage Therapy With Idarubicin in Immunocompetent Patients With Relapsed or Refractory Primary Central Nervous System Lymphomas |
| Lead sponsor | International Extranodal Lymphoma Study Group (IELSG), Other |
| Status | Terminated |
| Phase | Phase 2 |
| Study type | Interventional |
| Conditions | Lymphoma, B-Cell |
| Intervention type | Drug |
| Interventions | Idarubicin |
| Enrollment | 25 |
| Start date | Nov 1, 2004 |
| Primary completion | Jul 1, 2010 |
| First posted | Sep 21, 2005 |
| Last update posted | Jul 30, 2010 |
| Countries | Italy |
At a glance
- 1–9 Study sites
- No Results posted
- None Linked FDA submissions
Counts are shown as ranges. Exact figures, trends and every underlying record are available in Orca1.
About ClinicalTrials.gov studies
ClinicalTrials.gov is the U.S. National Library of Medicine's registry of clinical studies conducted around the world. Contact and investigator details are not shown here.
Source: U.S. National Library of Medicine (NLM), ClinicalTrials.gov · Source date: